Short-term improved vascular function after consuming red raspberries

A recent randomized controlled trial, published in the Archives of Biochemistry and Biophysics, provides insights on the promising outcomes of short-term improvements in blood vessel function among healthy males who consumed dietary achievable amounts of red raspberries. The subjects - ten healthy males aged 18 to 35 - consumed drinks prepared with 200g and 400g of frozen raspberries containing 201 or 403 mg of total polyphenols, or a matched control drink in terms of macro and micronutrient content, color, and taste.

Researchers investigated the vascular effects of the subjects at baseline, 2 hours-post consumption and 24 hours-post consumption of the raspberry and control test drinks. Participants consuming the red raspberry drink showed improved flow-mediated dilation (FMD), an established biomarker of cardiovascular disease risk. FMD increased significantly at 2 hours post-consumption of the raspberry drink when compared with the change in FMD due to the control drink, and this maintained at 24 hours after consumption.

At 2 hours post-consumption of both raspberry drinks, ellagic acid, found in plasma and urine correlated with FMD. At 24 hours post-consumption of the 200g raspberry drink, urolithin-A-3-glucuronide and urolithin-A-sulfate correlated with FMD. No significant differences were found between FMD improvements after consumption of the 200g and 400g raspberry drinks.

"The research study suggests that ellagitannins, a type of natural compounds present in red raspberries, may play a role in driving the positive effects seen on blood vessel function in the study's participants," commented Dr. Ana Rodriguez-Mateos, principal investigator and senior author of the study from the Department of Nutritional Sciences, Faculty of Life Sciences and Medicine of King's College London.

"We're excited about these findings and what they may potentially add to the growing list of benefits from consuming red raspberries," commented Tom Krugman, Executive Director of the National Processed Raspberry Council (NPRC).

Further studies will need to show whether these results translate into long-term health benefits in the general population by looking at larger study groups over longer timeframes.

Istas G, Feliciano RP, Weber T, Garcia-Villalba R, Tomas-Barberan F, Heiss C, Rodriguez-Mateos A.
Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: A double-blind randomized controlled trial.
Arch Biochem Biophys. 2018 Aug 1;651:43-51. doi: 10.1016/j.abb.2018.05.016.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...